Journals / Çocuk Enfeksiyon Dergisi / 2013 / Cilt: 7 - Sayı: 1

Çok sayıda transfüzyon alan hematolojik hastalıklı çocuklarda hepatit B, hepatit C ve insan immün yetmezlik virüs riski

The risk of hepatitis B, hepatitis C and human immunodeficiency virus in multitransfused children with hematological diseases

Pages
21–24
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A prospective, multicentre study is required to estimate hepatitis and HIV trans- mission risks more precisely. (J Pediatr Inf 2013; 7: 21-4)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Children with hematological diseases, who had received at least three transfusions, were included to estimate the transmission risks of hepati- tis B (HBV), hepatitis C (HCV) and human immunode- ficiency virus (HIV) infections through blood transfu- sions at a Pediatric Hematology Clinic in Ankara, Turkey.
📊
Key Findings & Data:Sami Ulus Children’s Hospital, Pediatric Hematology Department, through 1 January 2004-1 June 2008.
💡
Conclusion & Impact:A prospective, multicentre study is required to estimate hepatitis and HIV trans- mission risks more precisely. (J Pediatr Inf 2013; 7: 21-4)
🔬Design:Research Article
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Children with hematological diseases, who had received at least three transfusions, were included to estimate the transmission risks of hepati- tis B (HBV), hepatitis C (HCV) and human immunode- ficiency virus (HIV) infections through blood transfu- sions at a Pediatric Hematology Clinic in Ankara, Turkey. Material and Methods: This study was conducted at Dr. Sami Ulus Children’s Hospital, Pediatric Hematology Department, through 1 January 2004-1 June 2008. Children with the diagnoses of anemia, coagulation factor deficiency or leukemia and who had no antigen positivity for HBV, HCV or HIV at their first admission, were recruited retrospectively. After receiving three and more transfusions, their serologic results were re-evaluated for HBV, HCV and HIV. Results: The study included a total of 220 children, of whom 59.1% were boys. The mean age was 9.1±4.25 years. After transfusion of 9402 units of blood products, the seroconversion rates were: HBsAg 5.9% (n=13), antiHCV 1.4% (n=3) and anti HIV 0%. Conclusion: The estimated risk HBV infection in chil- dren with leukemia and aplastic anemia, receiving multiple blood transfusions was surprisingly higher than the other groups. A prospective, multicentre study is required to estimate hepatitis and HIV trans- mission risks more precisely. (J Pediatr Inf 2013; 7: 21-4)

Özet

Amaç: Ankara’da bir Pediyatrik Hematoloji Kliniği'nde, en az üç defa transfüzyon yapılmış, hematolojik has- talığı olan çocuklarda, kan transfüzyonu ile geçen hepatit B (HBV), hepatit C (HCV) ve insan immün yetmezlik virüsü (HİV) enfeksiyonları riski değerlendi- rilmesi yapıldı. Gereç ve Yöntemler: Bu çalışma, Dr. Sami Ulus Çocuk Hastanesi, Pediatrik Hematoloji Bölümü’nde 1 Ocak 2004-1 Haziran 2008 tarihleri arasında yapıldı. Anemi, pıhtılaşma faktörü eksikliği veya lösemi tanıla- rı olan, ve ilk başvurularında HBV, HCV veya HİV saptanmayan çocuk hastalar geriye dönük olarak toplandı. Kan ürünü transfüzyonları öncesinde, ve üç ve daha fazla transfüzyon aldıktan sonra, bunların HBV, HCV ve HİV serolojilerinin sonuçları tekrar ince- lendi. Bulgular: Çalışmaya alınan 220 çocuktan %59.1'i (n=130) erkekti. Ortalama yaş 9.1±4.25 olarak bulun- du. Toplam 9402 ünite kan ürünü transfüzyonu son- rası serokonversiyon oranları şöyleydi: HBsAg %5.9 (n=13), antiHCV %1.4 (n=3) ve antiHİV %0. Sonuç: Lösemi ve aplastik anemisi olan ve çok sayı- da kan transfüzyonu alan çocuklarda gözlenen HBV riski şaşırtıcı olarak diğer gruplardan yüksek bulun- muştur. İleriye dönük, çok merkezli bir çalışma ile hepatit ve HİV’in kan ürünleriyle geçiş risklerinin daha kesin olarak belirlenmesi gereklidir. (J Pediatr Inf 2013; 7: 21-4)

🔖

Cite This Article

ÜNSAL, R. S., YARALI, H. N., GÜNGÖR, S., KARA, A., IŞIK, P., ÖZKASAP, S., BAY, A., TUNÇ, B. (2013). Çok sayıda transfüzyon alan hematolojik hastalıklı çocuklarda hepatit B, hepatit C ve insan immün yetmezlik virüs riski. Çocuk Enfeksiyon Dergisi, Cilt: 7 - Sayı: 1, 21–24. https://ajindex.com/articles/348713

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Stramer SL. Current risks of transfusion-treatment agents. A review. Arch Pathol Lab Med. 2007; 131: 702-7
  2. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007; 370: 415-26. [CrossRef] 3. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007; 370: 427-38. [CrossRef] 4. Despotis GJ, Zhang L, Lublin DM. Transfusion risks and trans- fusion-related pro-inflammatory responses. Hematol Oncol Clin North Am 2007; 21: 147-61. [CrossRef 5. Sloan SR, Friedman DF, Kao G, et al. Transfusion medicine. In: Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE (editors). Nathan and Oski’s Hematology of Infancy and Childhood. 7th ed. Philadelphia: Saunders 2009.pp.1636-9
  3. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011; 100: 92-8. [CrossRef] 7. Epstein JS. Alternative strategies in assuring blood safety: An overview. Biologicals 2010; 38: 31-5. [CrossRef] 8. Gurol E, Saban C, Oral O, Cigdem A, Armagan A. Trends in hepatitis B and hepatitis C virus among blood donors over 16 years in Turkey. Eur J Epidemiol 2006; 21: 299-305. [CrossRef] 9. Acar A, Kemahli S, Altunay H, et al. HBV, HCV and HIV serop- revalence among blood donors in Istanbul, Turkey: how effec- tive are the changes in the national blood transfusion policies? Braz J Infect Dis 2010; 14: 41-6. [CrossRef] 10. The Ministry of Health of Turkey. Health Statistics Year Book 2008. http://www.saglik.gov.tr/TR/dosya/1-63660/h/2008.pdf (Accessed 21/01/2011)
  4. Berberoğlu S. The seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus infections in paediatric oncology patients in Turkey. Postgrad Med J 1996; 72: 609-11. [CrossRef] 12. Ozyurek E, Ergunay K, Kuskonmaz B, et al. Transfusion- transmitted virus prevalence in Turkish patients with thalas- semia. Pediatr Hematol Oncol 2006; 4: 347-53. [CrossRef] 13. Vinelli E, Lorenzana I. Transfusion-transmitted infections in multi- transfused patients in Honduras. J Clin Virol 2005; 34: 53-60. [CrossRef] 14. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive- induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 15: 391-6. [CrossRef] 15. Baytan B, Gunes A M, Gunay U. Efficacy of primary hepatitis B immunization in children with acute lymphoblastic leukemia. Indian Pediatr 2008; 45: 265-70
  5. Yetgin S, Tav